| Literature DB >> 27198854 |
Robert V Kolakowski1, Karl T Haelsig2, Kim K Emmerton2, Chris I Leiske2, Jamie B Miyamoto2, Julia H Cochran2, Robert P Lyon2, Peter D Senter2, Scott C Jeffrey3.
Abstract
A strategy for the conjugation of alcohol-containing payloads to antibodies has been developed and involves the methylene alkoxy carbamate (MAC) self-immolative unit. A series of MAC β-glucuronide model constructs were prepared to evaluate stability and enzymatic release, and the results demonstrated high stability at physiological pH in a substitution-dependent manner. All the MAC model compounds efficiently released alcohol drug surrogates under the action of β-glucuronidase. To assess the MAC technology for ADCs, the potent microtubule-disrupting agent auristatin E (AE) was incorporated through the norephedrine alcohol. Conjugation of the MAC β-glucuronide AE drug linker to the anti-CD30 antibody cAC10, and an IgG control antibody, gave potent and immunologically specific activities in vitro and in vivo. These studies validate the MAC self-immolative unit for alcohol-containing payloads within ADCs, a class that has not been widely exploited.Entities:
Keywords: alcohols; antibodies; cancer; drug delivery; glycoconjugate
Mesh:
Substances:
Year: 2016 PMID: 27198854 DOI: 10.1002/anie.201601506
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336